Merck reported modest earnings growth but lowered guidance for key products like GARDASIL and SINGULAIR, introducing uncertainty with the suspension of full-year EPS projections due to the SEAS study. While cost-saving measures and strong international performance provide some offset, the lack of clear future guidance is likely to weigh on investor confidence in the short term.

[-1]